List of Excipients in Branded Drug LIVMARLI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mirum Pharmaceuticals Inc	LIVMARLI	maralixibat chloride	79378-110	EDETATE DISODIUM	2031-07-24
Mirum Pharmaceuticals Inc	LIVMARLI	maralixibat chloride	79378-110	PROPYLENE GLYCOL	2031-07-24
Mirum Pharmaceuticals Inc	LIVMARLI	maralixibat chloride	79378-110	SUCRALOSE	2031-07-24

Livmarli Excipient Strategy and Commercial Opportunities

Last updated: August 13, 2026

Livmarli, Mirum Pharmaceuticals’ maralixibat oral solution, has a commercially important excipient profile because it targets infants and children with chronic cholestatic liver disease. Its 9.5 mg/mL liquid formulation supports weight-based dosing, avoids swallowing barriers, and enables outpatient treatment. The main commercial opportunities are pediatric taste masking, dose-measuring systems, preservative and container optimization, global reformulation, generic or 505(b)(2) development, and excipient supply agreements.

What is Livmarli and how is it administered?

Livmarli contains maralixibat chloride, an apical sodium-dependent bile acid transporter inhibitor. The U.S. product is an oral solution with a concentration of 9.5 mg maralixibat chloride per mL, equivalent to 9 mg maralixibat per mL.[1]

Attribute	Livmarli profile
Active ingredient	Maralixibat chloride
Brand owner	Mirum Pharmaceuticals
Dosage form	Oral solution
Strength	9.5 mg/mL maralixibat chloride
Primary U.S. indications	Cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis
Patient population	Infants, children and adolescents, depending on indication and label
Administration	Once daily, with dosing based on body weight and indication
Key delivery requirement	Accurate measurement of small pediatric volumes
Regulatory status	FDA-approved prescription drug
Formulation risk	Taste, dosing accuracy, preservative exposure and container compatibility

The FDA approved Livmarli for cholestatic pruritus in patients with Alagille syndrome in 2021. The agency expanded the product’s U.S. indication to patients with progressive familial intrahepatic cholestasis in 2023.[1,2]

What excipients are used in Livmarli?

The FDA prescribing information identifies glycerin, hypromellose, sodium benzoate, sucralose and water among the inactive ingredients in Livmarli oral solution.[1]

Functional role of the principal excipients

Excipient	Likely formulation function	Commercial relevance
Glycerin	Humectant, solvent and mouthfeel modifier	Supports liquid texture and palatability
Hypromellose	Viscosity modifier and suspending aid	Helps control flow and dose uniformity
Sodium benzoate	Antimicrobial preservative	Supports multidose packaging and shelf life
Sucralose	High-intensity sweetener	Reduces bitterness and improves pediatric acceptability
Purified water	Primary vehicle	Controls concentration, viscosity and microbial risk

The excipient system is consistent with a multidose pediatric oral liquid. Sucralose addresses taste, hypromellose controls rheology, glycerin improves mouthfeel, and sodium benzoate reduces microbial growth risk. This combination also supports a relatively simple manufacturing process compared with a suspension, lipid formulation or sterile liquid.

The commercial value of the formulation lies less in excipient novelty than in the integration of excipients with pediatric dosing, chronic use and regulatory requirements.

Why does the excipient strategy matter for pediatric use?

Livmarli is administered to patients who may be infants or young children. Pediatric oral liquids must address five formulation problems:

1. The patient may be unable to swallow tablets or capsules.
2. Doses change as body weight changes.
3. Small dosing errors can materially affect exposure.
4. Taste can determine adherence.
5. Chronic treatment increases the importance of preservative tolerability and caregiver convenience.

A 9.5 mg/mL solution eliminates the redispersion problem associated with suspensions. A caregiver does not need to shake the product to distribute suspended particles, although normal product handling and measurement instructions remain important. The solution format also permits dose changes without replacing the dosage form.

Hypromellose may increase viscosity enough to improve dosing control, but excessive viscosity can slow withdrawal from a syringe and increase residual volume. That creates an opportunity for device and formulation optimization rather than simple excipient substitution.

What formulation patents protect Livmarli?

Livmarli’s commercial protection is expected to depend primarily on maralixibat composition, therapeutic use, pharmaceutical compositions and regulatory exclusivities rather than on a single widely recognized excipient patent.

The relevant protection categories are:

Protection category	Relevance to Livmarli
Active-ingredient patents	Protect maralixibat or maralixibat salts and related chemical matter
Method-of-use patents	Cover treatment of cholestatic diseases, pruritus or related liver conditions
Pharmaceutical-composition patents	May cover dosage forms, concentration ranges or delivery systems
Manufacturing patents	May cover synthesis, purification, salt formation or solid-state properties
Pediatric regulatory exclusivity	Can delay approval of certain competing applications
Orphan-drug exclusivity	May restrict approval of the same drug for the protected indication
Trademark protection	Protects the Livmarli brand but does not block alternative formulations using maralixibat

An excipient combination can be patentable if it provides a demonstrated technical benefit, such as improved stability, reduced degradation, enhanced palatability or reduced dosing variability. A conventional combination of glycerin, hypromellose, sodium benzoate and sucralose is more vulnerable to obviousness challenges unless supported by comparative data.

A competitive formulation developer should therefore avoid relying on a direct copy of the branded excipient system. A differentiated product could use a different sweetener, preservative system, viscosity modifier, container or dosing device, subject to stability, pediatric safety and regulatory requirements.

When does Livmarli lose exclusivity?

Livmarli’s exclusivity timeline has several components rather than one single expiration date.

Regulatory exclusivity

The FDA granted Livmarli orphan-drug designation for Alagille syndrome and progressive familial intrahepatic cholestasis. Orphan-drug exclusivity generally lasts seven years from approval for the relevant indication, subject to the scope of the designation and statutory exceptions.[3]

The Alagille syndrome approval occurred in 2021. The PFIC approval occurred in 2023. These dates create separate commercial barriers by indication, although the practical impact depends on the exact scope of the orphan designations and any competing products.

Patent exclusivity

Patent expiration depends on the specific U.S. patents listed for Livmarli in the FDA Orange Book and on any patent-term adjustment or extension. A precise launch analysis must distinguish:

• expiration of active-ingredient claims;
• expiration of method-of-use claims;
• expiration of formulation or composition claims;
• pediatric patent-term extensions;
• settlement restrictions;
• the statutory basis of a proposed generic or 505(b)(2) application.

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity codes.[4] A generic applicant could challenge listed patents through a Paragraph IV certification, while a 505(b)(2) applicant could pursue a different formulation or route while addressing listed patents and exclusivities.

What commercial opportunities exist for excipient suppliers?

Pediatric taste-masking systems

Taste is one of the strongest commercial opportunities. Maralixibat treatment can be chronic, and adherence depends on caregiver acceptance and child tolerance. Suppliers can offer:

• low-calorie sweetener systems;
• flavor systems compatible with acidic or preservative-containing liquids;
• bitterness suppression;
• reduced aftertaste;
• flavor stability over the product shelf life.

A substitute flavor or sweetener must be assessed against the product’s pH, preservative concentration, container closure and active-ingredient stability.

Preservative alternatives

Sodium benzoate is functional for multidose packaging but creates an opportunity for alternative systems. Potential approaches include:

• potassium sorbate;
• benzoate-free preservation;
• lower-preservative systems combined with improved packaging;
• unit-dose packaging;
• microbial-control packaging components.

For pediatric products, preservative substitution requires careful evaluation of exposure, microbial challenge testing, pH dependence and regulatory acceptability. A preservative-free multidose product may require a more complex container or a shorter in-use period.

Dosing devices

Dose measurement is a material commercial opportunity. A calibrated oral syringe, bottle adapter or unit-dose dispenser can reduce caregiver error. Device improvements may include:

• low-dead-space syringes;
• bottle adapters that minimize leakage;
• tactile or color-coded dose markings;
• dose tracking;
• age-specific delivery accessories;
• tamper-evident and child-resistant packaging.

Device manufacturers can compete even if the liquid formulation remains unchanged. The strongest opportunity is a formulation-device combination that reduces residual volume and improves dosing accuracy.

Alternate dosage forms

A tablet, dispersible tablet, sprinkle capsule or granule formulation could expand use among older children and adults. The main development challenge is retaining flexible weight-based dosing while improving convenience.

Potential products include:

Product concept	Commercial rationale	Main barrier
Oral granules	Easier transport and potentially improved stability	Taste, dose uniformity and pediatric administration
Dispersible tablet	Lower shipping burden and improved portability	Dose flexibility and palatability
Mini-tablet	Suitable for older children	Swallowing and dose titration
Unit-dose liquid	Lower contamination risk	Higher packaging cost
Concentrated solution	Smaller administration volume	Dose-measurement and tolerability risk
Long-acting formulation	Reduced dosing frequency	Complex development and uncertain pediatric acceptability

How strong is the commercial formulation position?

Livmarli has a strong product-format position but a less certain excipient moat.

Strengths

• Liquid dosing is well matched to infants and young children.
• Once-daily administration supports caregiver convenience.
• A solution avoids suspension redispersion problems.
• The product addresses rare diseases with limited approved competition.
• Chronic treatment increases the value of adherence-supporting formulation features.
• Maralixibat has two approved U.S. disease indications.

Vulnerabilities

• Conventional excipients may be replaceable.
• A competitor may use a different liquid formulation or solid dosage form.
• Pediatric oral liquids can be designed around the same active ingredient without duplicating every excipient.
• The commercial barrier may be driven more by orphan exclusivity and active-ingredient patents than by formulation IP.
• A generic or 505(b)(2) applicant could target older patients with an alternative dosage form.

The formulation estate would be stronger if Mirum has issued claims covering specific concentration ranges, stability performance, taste masking, preservative systems, device integration or manufacturing controls. Those claims must be assessed patent by patent in the current Orange Book and USPTO records.

What generic entry risks exist for Livmarli?

Abbreviated new drug application risk

A conventional ANDA applicant would need to demonstrate pharmaceutical equivalence and bioequivalence, subject to FDA requirements for the product. Differences in inactive ingredients may be permitted if they do not affect safety, efficacy, manufacturability or performance.

For a pediatric oral solution, the applicant may face issues involving:

• concentration equivalence;
• viscosity;
• dose-volume accuracy;
• preservative effectiveness;
• container closure;
• flavor and labeling;
• measurement-device compatibility.

505(b)(2) risk

A 505(b)(2) applicant could pursue a modified product, such as a concentrated liquid, granule or dispersible tablet. This route may create a more differentiated commercial product but also exposes the applicant to additional clinical, pharmaceutical-development and patent considerations.

A 505(b)(2) product may compete first in older children or adults, where a tablet or smaller-volume dosage form has a stronger value proposition than the branded pediatric liquid.

Which companies are challenging or competing with Livmarli?

Direct commercial competition is limited because Livmarli treats rare cholestatic disorders. Competitive pressure comes from three sources:

1. Existing medical management, including supportive treatment and disease-specific interventions.
2. Other bile acid pathway products, including odevixibat, depending on indication and jurisdiction.
3. Future maralixibat generics, 505(b)(2) products and competing transporter inhibitors.

Odevixibat, marketed as Bylvay by Albireo and later Ipsen, is a relevant comparator because it is also an ileal bile acid transport inhibitor used in rare cholestatic diseases.[5] The products compete on indication coverage, age eligibility, dosage form, dosing frequency, tolerability, reimbursement and geographic availability.

Factor	Livmarli	Odevixibat
Mechanism class	IBAT inhibitor	IBAT inhibitor
Main commercial format	Oral solution	Oral pellets and related oral dosage forms
Pediatric positioning	Strong fit for infants and young children	Strong fit for pediatric rare-disease use
Excipient opportunity	Liquid taste, viscosity and syringe delivery	Pellet palatability, dispersibility and administration
Competitive issue	Chronic liquid adherence and device convenience	Granule or pellet portability and dosage flexibility

What manufacturing and IP barriers affect excipient opportunities?

Manufacturing barriers are moderate for the oral solution but can become significant during substitution. A reformulated product must control:

• active-ingredient assay;
• degradation products;
• pH;
• viscosity;
• preservative effectiveness;
• microbial limits;
• extractables and leachables;
• fill-volume accuracy;
• bottle and syringe compatibility;
• in-use stability after opening.

Changing an excipient can alter the chemical environment around maralixibat. A new preservative may change pH or degradation kinetics. A different sweetener may interact with the active ingredient or packaging. A lower-viscosity system may improve syringe performance but increase dosing variability.

The strongest IP opportunity is a validated formulation advantage. Examples include a defined pH range that improves stability, a preservative system with lower pediatric exposure, or a device-compatible liquid that reduces residual dose loss. Broad claims based only on routine excipient selection are less defensible.

What is the FDA regulatory status of Livmarli?

Livmarli is an FDA-approved prescription oral solution. Its U.S. regulatory history includes approval for Alagille syndrome and a later indication for PFIC.[1,2]

The product’s pediatric positioning creates regulatory value because formulation changes must account for age-specific administration, safety and acceptability. A new excipient or alternative dosage form may require comparative pharmaceutical data and, depending on the regulatory pathway, additional clinical evidence.

For an excipient supplier, the most attractive development target is an excipient already supported in pediatric oral liquids and accepted across the major jurisdictions. Novel excipients could offer differentiation but would carry greater regulatory and development risk.

What is the revenue exposure and market opportunity?

Livmarli addresses small patient populations but has high annual treatment value because it is used for rare, chronic liver diseases. Revenue exposure is concentrated in:

• U.S. orphan-drug pricing;
• payer coverage;
• diagnosis rates;
• treatment duration;
• expansion into additional geographies;
• adoption in younger patients;
• competition from other IBAT inhibitors.

Mirum has reported Livmarli as a central commercial product within its rare-disease portfolio.[6] A formulation improvement that increases adherence, reduces caregiver burden or lowers shipping and administration costs could support premium positioning even without changing the active ingredient.

For excipient companies, the addressable opportunity is narrower than the value of the drug itself. The most realistic revenue channels are supply contracts, formulation-development partnerships, device integration and licensing of taste-masking or packaging technology.

Key Takeaways

• Livmarli is a 9.5 mg/mL maralixibat oral solution designed for chronic pediatric use.
• Its disclosed excipient system includes glycerin, hypromellose, sodium benzoate, sucralose and water.
• Taste masking, viscosity control, preservation and dose measurement are the main formulation functions.
• The strongest commercial opportunities are pediatric flavor systems, alternative preservatives, oral syringes, unit-dose packaging and age-specific dosage forms.
• The product’s main competitive moat is likely to come from maralixibat patents, method-of-use protection, orphan exclusivity and market access rather than from conventional excipients alone.
• Generic and 505(b)(2) risks increase as active-ingredient and indication exclusivities expire.
• Odevixibat is the principal mechanistic comparator in rare cholestatic disease, although the products differ in dosage-form strategy.
• A commercially valuable reformulation should demonstrate measurable improvements in stability, palatability, dosing accuracy, preservative exposure or administration convenience.

FAQs About Livmarli Excipient and Formulation Opportunities

Can a generic Livmarli use different excipients?

Yes. A generic oral solution may use different inactive ingredients if it meets FDA requirements for safety, quality, performance and pharmaceutical equivalence.

Is Livmarli a suspension or a solution?

Livmarli is an oral solution. This avoids the redispersion and particle-settling issues associated with suspensions.

Which excipient is most important for Livmarli taste?

Sucralose is the principal disclosed sweetener. Flavor performance also depends on the active ingredient, pH, glycerin, preservative system and any flavoring components.

Could Livmarli be reformulated as a tablet?

A tablet, mini-tablet, granule or dispersible dosage form could be developed, especially for older children and adults. The main challenges are weight-based dose flexibility, palatability and regulatory bridging.

Does Livmarli have biosimilar competition?

No. Livmarli is a small-molecule drug, not a biologic. Future competition would involve generics, 505(b)(2) products or other small-molecule bile acid transporter inhibitors, not biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Livmarli (maralixibat) oral solution prescribing information.
2. U.S. Food and Drug Administration. (2023). FDA approves Livmarli for patients with progressive familial intrahepatic cholestasis.
3. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. European Medicines Agency. (2023). Bylvay: EPAR product information.
6. Mirum Pharmaceuticals, Inc. (2024). Annual report on Form 10-K.